Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

cyanotech - CYAN

CYAN

Close Chg Chg %
0.44 0.01 2.97%

Closed Market

0.45

+0.01 (2.97%)

Volume: 1.70K

Last Updated:

Dec 11, 2025, 11:16 AM EDT

Trade Now

Company Overview: cyanotech - CYAN

CYAN Key Data

Open

$0.40

 Day Range

0.40 - 0.45

52 Week Range

0.21 - 0.57

 Market Cap

$3.25M

Shares Outstanding

7.39M

 Public Float

3.98M

Beta

-0.08

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$0.25

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

5.13K

  

CYAN Performance

1 Week
 
 -4.26%
 
1 Month
 
 12.50%
 
3 Months
 
 53.85%
 
1 Year
 
 55.17%
 
5 Years
 
 -85.10%
 

CYAN Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About cyanotech - CYAN

Cyanotech Corp. engages in the cultivation, production, and sale of natural products derived from microalgae for the health and human nutrition markets worldwide. Its products include BioAstin Hawaiian Astaxanthin, a dietary antioxidant, which is used as a human dietary supplement and dietary ingredient to support and maintain the body's natural inflammatory response, enhance skin, and support eye, joint, and immune health, and Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement that is used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. The company was founded by Gerald R. Cysewski in 1983 and is headquartered in Kailua-Kona, HI.

CYAN At a Glance

Cyanotech Corp.
73-4460 Queen Kaahumanu Highway
Kailua-Kona, Hawaii 96740-2637
Phone 1-808-326-1353 Revenue 24.22M
Industry Pharmaceuticals: Other Net Income -3,203,000.00
Sector Health Technology 2025 Sales Growth 4.959%
Fiscal Year-end 03 / 2026 Employees 83
View SEC Filings

CYAN Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.102
Price to Book Ratio 0.284
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -21.911
Enterprise Value to Sales 0.569
Total Debt to Enterprise Value 0.839

CYAN Efficiency

Revenue/Employee 291,746.988
Income Per Employee -38,590.361
Receivables Turnover 12.399
Total Asset Turnover 0.996

CYAN Liquidity

Current Ratio 1.029
Quick Ratio 0.269
Cash Ratio 0.025

CYAN Profitability

Gross Margin 28.396
Operating Margin -10.357
Pretax Margin -13.194
Net Margin -13.227
Return on Assets -13.181
Return on Equity -30.95
Return on Total Capital -15.664
Return on Invested Capital -21.493

CYAN Capital Structure

Total Debt to Total Equity 130.167
Total Debt to Total Capital 56.553
Total Debt to Total Assets 49.229
Long-Term Debt to Equity 49.111
Long-Term Debt to Total Capital 21.337
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Cyanotech - CYAN

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
35.97M 23.18M 23.07M 24.21M
Sales Growth
+11.20% -35.56% -0.46% +4.96%
Cost of Goods Sold (COGS) incl D&A
22.40M 15.92M 17.13M 17.34M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.92M 2.10M 2.08M 1.88M
Depreciation
1.92M 2.10M 2.08M 1.88M
Amortization of Intangibles
- - - -
-
COGS Growth
+5.53% -28.94% +7.58% +1.24%
Gross Income
13.57M 7.26M 5.95M 6.88M
Gross Income Growth
+22.03% -46.49% -18.10% +15.66%
Gross Profit Margin
+37.72% +31.32% +25.77% +28.40%
2022 2023 2024 2025 5-year trend
SG&A Expense
10.99M 10.18M 10.54M 9.38M
Research & Development
712.00K 770.00K 689.00K 449.00K
Other SG&A
10.28M 9.41M 9.85M 8.94M
SGA Growth
-0.37% -7.40% +3.52% -10.94%
Other Operating Expense
- - - -
-
Unusual Expense
- - 21.00K 5.00K
-
EBIT after Unusual Expense
2.55M (2.92M) (4.59M) (2.51M)
Non Operating Income/Expense
- - - -
-
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
371.00K 497.00K 668.00K 687.00K
Interest Expense Growth
-32.55% +33.96% +34.41% +2.84%
Gross Interest Expense
371.00K 497.00K 668.00K 687.00K
Interest Capitalized
- - - -
-
Pretax Income
2.18M (3.42M) (5.26M) (3.19M)
Pretax Income Growth
+136.40% -256.83% -53.71% +39.26%
Pretax Margin
+6.07% -14.76% -22.80% -13.19%
Income Tax
28.00K 18.00K 7.00K 8.00K
Income Tax - Current - Domestic
28.00K 18.00K 7.00K 8.00K
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
2.15M (3.44M) (5.27M) (3.20M)
Minority Interest Expense
- - - -
-
Net Income
2.15M (3.44M) (5.27M) (3.20M)
Net Income Growth
+134.13% -259.70% -53.11% +39.19%
Net Margin Growth
+5.99% -14.84% -22.83% -13.23%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
2.15M (3.44M) (5.27M) (3.20M)
Preferred Dividends
- - - -
-
Net Income Available to Common
2.15M (3.44M) (5.27M) (3.20M)
EPS (Basic)
0.3498 -0.5509 -0.8065 -0.453
EPS (Basic) Growth
+130.74% -257.49% -46.40% +43.83%
Basic Shares Outstanding
6.16M 6.24M 6.53M 7.07M
EPS (Diluted)
0.3492 -0.5509 -0.8065 -0.453
EPS (Diluted) Growth
+135.31% -257.76% -46.40% +43.83%
Diluted Shares Outstanding
6.17M 6.24M 6.53M 7.07M
EBITDA
4.50M (825.00K) (2.51M) (629.00K)
EBITDA Growth
+109.17% -118.35% -204.36% +74.95%
EBITDA Margin
+12.50% -3.56% -10.88% -2.60%

Insider Actions for Cyanotech - CYAN

Date Name Shares Transaction Value
Sep 17, 2025 Jennifer Miyashiro CFO, VP Fin & Admin, Treasurer 50,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 1, 2025 Matthew K. Custer President and CEO; Director 6,754 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 1, 2025 Amy Beth Nordin VP, HR, Secretary 34 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 1, 2025 Amy Beth Nordin VP, HR, Secretary 9,051 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.4 per share 3,620.40
Aug 1, 2025 Amy Beth Nordin VP, HR, Secretary 9,576 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 1, 2025 Matthew K. Custer President and CEO; Director 64,137 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 22, 2025 Glenn D. Jensen VP, Operations 25,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 21, 2025 Jennifer M. Johansen VP, Quality, Regulatory & Govt 10,062 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 21, 2025 Jennifer M. Johansen VP, Quality, Regulatory & Govt 8,861 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.4 per share 3,544.40
Feb 21, 2025 Jennifer M. Johansen VP, Quality, Regulatory & Govt 1,447 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 21, 2025 Gerald R. Cysewski 147,156 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 21, 2025 Glenn D. Jensen VP, Operations 1,709 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 21, 2025 Glenn D. Jensen VP, Operations 26,065 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.4 per share 10,426.00
Feb 21, 2025 Gerald R. Cysewski 1,644 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 21, 2025 Collette Kakuk Chief Strategic Comml Officer 6,244 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 21, 2025 Collette Kakuk Chief Strategic Comml Officer 4,688 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.4 per share 1,875.20
Feb 21, 2025 Collette Kakuk Chief Strategic Comml Officer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 21, 2025 Gerald R. Cysewski 145,692 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.4 per share 58,276.80

Cyanotech in the News